SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SARS and Avian Flu

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche1/24/2007 1:39:29 PM
   of 4232
 
two stories, morphed into one.......

newscientist.com

Deadly H5N1 may be brewing in cats
24 January 2007

Debora Mackenzie

Bird flu hasn't gone away. The discovery, announced last week, that the H5N1 bird flu virus is widespread in cats in locations across Indonesia has refocused attention on the danger that the deadly virus could be mutating into a form that can infect humans far more easily.

In the first survey of its kind, an Indonesian scientist has found that in areas where there have been outbreaks of H5N1 in poultry and humans, 1 in 5 cats have been infected with the virus, and survived. This suggests that as outbreaks continue to flare across Asia and Africa, H5N1 will have vastly more opportunities to adapt to mammals than had been supposed.

Chairul Anwar Nidom of Airlangga University in Surabaya, Indonesia, told journalists last week that he had taken blood samples from 500 stray cats near poultry markets in four areas of Java, including the capital, Jakarta, and one area in Sumatra, all of which have recently had outbreaks of H5N1 in poultry and people.

Of these cats, 20 per cent carried antibodies to H5N1. This does not mean that they were still carrying the virus, only that they had been infected - probably through eating birds that had H5N1. Many other cats that were infected are likely to have died from the resulting illness, so many more than 20 per cent of the original cat populations may have acquired H5N1.

This is a much higher rate of infection than has been found in surveys of apparently healthy birds in Asia. "I am quite taken aback by the results," says Nidom, who also found the virus in Indonesian pigs in 2005. He plans further tests of the samples at the University of Tokyo in February.

Amin Soebandrio, head of medical sciences at the Indonesian ministry for research and technology, confirmed the report. He says that the infection has also been found in dogs and cats on the Indonesian island of Bali, which has also had outbreaks of H5N1. The new findings follow reports that unusually large numbers of dead cats have been found near many outbreaks of H5N1. "Javanese farmers even have a word for the cat disease," says Albert Osterhaus of Erasmus University in Rotterdam, the Netherlands. It was Osterhaus's lab which in 2004 found that cats can catch the H5N1 virus. Like humans, some cats die, and some recover. But unlike humans, infected cats shed large amounts of the virus and pass it to each other.

Infected cats may not directly increase the danger of people catching the virus, as humans seem to catch the current strain only with difficulty even from birds, which they kill, pluck and eat. The main worry, says Osterhaus, is that as the virus replicates in cats it will further adapt to mammals and acquire the ability to spread more efficiently to people and from person to person, unleashing a human pandemic.

Nidom's findings are the first to indicate what proportion of cats can become infected by H5N1. No cats have been tested in Hong Kong or China. In Bangkok, Thailand, all the cats in one household are known to have died of H5N1 in 2004. Tigers and leopards in Thai zoos also died, while last year two cats near an outbreak in poultry and people in Iraq were confirmed to have died of H5N1, as were three German cats that ate wild birds. In Austria cats were infected but remained healthy (New Scientist, 18 March 2006, p 6).

Though Osterhaus says Nidom's figures must be confirmed, he says they aren't surprising, and is even encouraged that they aren't worse. A higher percentage of infected predators than prey makes sense, as each predator eats many prey animals. "At least that percentage shows the virus has not completely adapted to cats - yet," Osterhaus says. If it had, all cats in a stricken area should be infected, as with ordinary flu in humans.

Osterhaus emphasises that the cat infections still pose a potential threat. "We know the 1918 pandemic was a bird flu virus that adapted to mammals in some intermediate mammalian host, possibly pigs," he says. "Maybe for H5N1 the intermediate host is cats." If similar percentages of cats are infected at every outbreak location, there must have been many thousands of cat infections since the virus emerged, compared to 267 confirmed cases in humans. Every sick cat is a chance for the virus to adapt, and with renewed outbreaks this year in birds, people or both in China, Indonesia, Japan, South Korea, Hong Kong, Vietnam, Thailand, Egypt and Nigeria, it is getting plenty of such chances.

Killing cats won't solve the problem, Osterhaus warns. Like shooting wild birds, it is unlikely to have much impact and could send infected animals elsewhere. It would also lead to a population explosion of disease-carrying rodents, which the cats normally keep in check.

"Cats must just be kept from eating sick chickens," Osterhaus says, though this will be a tall order in open-air markets across Asia and Africa, which are typically swarming with hungry cats. In Jakarta this week, officials are slaughtering thousands of banned backyard poultry - then handing them back for their owners to eat. Some of the birds could well be infected despite appearing healthy. It is hard to imagine the local cats not getting their share.

From issue 2588 of New Scientist magazine, 24 January 2007, page 6-7

Will the drugs still work?

In late December, a man and his niece died of H5N1 flu in Gharbiyah province in Egypt's Nile delta. Both had been taking the antiviral drug Tamiflu and both were found to be infected with a virus containing a mutation that makes it partially resistant to the drug. They had been on Tamiflu for only two days, so the virus may already have been resistant when they caught it.

This is a worrying development. Tamiflu-resistant strains are not usually contagious because the mutations that make the virus resistant usually also cripple it. Countries with stockpiles of Tamiflu had been hoping this might limit the spread of drug-resistant strains during a pandemic, but resistance mutations have recently been seen that don't slow the virus's spread so much.

Marc Lipsitch and colleagues at the Harvard School of Public Health in Boston have used a computer model to assess the likely impact of such mutations. They showed that if a drug-resistance mutation emerges during a pandemic that cuts the virus's fitness by 20 per cent or less, the resistant strain will have so much advantage over non-resistant viruses that it will spread until perhaps a third or more of all cases are drug-resistant (PLoS Medicine, DOI: 10.1371/journal.pmed.0040015). This will happen, they predict, even if such strains emerge very rarely.

"This may mean fewer deaths, or more, depending on how the resistant virus behaves," says Lipsitch, who points to an unexpected bright spot of his team's findings. "What surprised us is that even if the resistant strain spreads quite widely, its emergence will delay the peak of the pandemic by as much as a year." This happens because the resistant strain is less fit and also because it takes time to get going.

This is good news because as much as possible needs to be done to provide a breathing space at the beginning of a pandemic. "The whole point is to delay the pandemic until we can get a good vaccine made," Lipsitch says. The model showed that it should be possible to extend such a delay by closing schools or giving people a partially effective pre-pandemic vaccine against H5 flu.

An even bigger computer model of a flu pandemic published in the same journal (PLoS Medicine, DOI: 10.1371/journal.pmed.0040013), echoes these findings. Alessandro Vespignani at Indiana University, Bloomington, and colleagues found that as long as every person infected with pandemic flu infects fewer than two more people, antivirals could delay the pandemic peak by a year. During the 1918 flu pandemic, each infected person is thought to have spread it to 1.8 people, on average.

Since few of the countries where a pandemic virus is most likely to emerge have adequate stockpiles of antivirals, rich countries will need to pitch in to achieve this. Strategically sharing just 10 per cent of their stockpiles should be enough to make this strategy work, the study suggests.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext